This paper is only available as a PDF. To read, Please Download here.
Firmly established tumors in syngeneic mice will regress if the host is challenged with living tumor cells which have been exposed to Vibrio cholerae neuraminidase (VCN) in vitro. The present study demonstrates that rapid freezing of the VCN-treated tumor challenge at −95 ° C. and storage at −70 ° C. does not interfere with its immunoregressive potency but does prevent regrowth of the tumor cells from the challenging vaccine. The clinical potential of this finding is discussed.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Immunogenicity of L 1210 murine leukemia cells after treatment with neuraminidase.Nature. 1968; 218: 1254
- Immunogenicity of leukemia L 1210 cells after neuraminidase treatment.J. Natl. Cancer Inst. 1972; 49: 107
- Immunogenicity of neuraminidase-treated 6C3HED lymphoma in C3H/HeJ and C3H/f mice.in: Proc. Am. Assoc. Cancer Res. 13. 1972: 113
- The fate of neuraminidase-treated leukemia L 1210 cells as an immunogen in non-immunized mice.in: Proc. Am. Assoc. Cancer Res. 14. 1973: 64
- Cytotoxic test for demonstration of mouse antibody.in: Methods in medical research. Yearbook Medical Publishers, Chicago1964: 39
- The role of sialic acid in antigenic expressions: Further studies of the Landschutz ascites tumour.Br. J. Cancer. 1968; 23: 843
- Tumour-specific immunogenicity of methyl-cholanthrene-induced sarcoma cells after incubation in neuraminidase.Br. J. Cancer. 1969; 23: 141
- Antigenic specificities on murine sarcoma cells: Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity.J. Exp. Med. 1971; 133: 1171
- Growth of tumors in allogeneic hosts after organ culture explanation. II. Tumor-host interactions.J. Natl. Cancer Inst. 1969; 42: 537
- Altered host-allograft relationships for mouse tumors modified by prior passage in vitro and in vivo.J. Natl. Cancer Inst. 1970; 45: 263
- Growth of tumors in allogeneic hosts following organ culture explanation.Transplantation. 1967; 5: 410
- Successful growth of tumor allografts following explanation: Effect of various culture conditions.in: Proc. Soc. Exp. Biol. Med. 127. 1968: 957
- Combination chemotherapy and immunotherapy of transplantable murine leukemia.in: Proc. Am. Assoc. Cancer Res. 14. 1973: 69
- Complement sensitivity of neuraminidase-treated lymphoid cells.Transplantation. 1971; 12: 327
- Failure of neuraminidase to unmask allogenic antigens on cell surfaces.in: Proc. Soc. Exp. Biol. Med. 138. 1971: 600
- Immunospecific regression of various syngeneic mouse, tumors in response to neuraminidase-treated tumor cells.J. Natl. Cancer Inst. 1973; 51: 637
- Further studies on the effect of neuraminidase on tumor cell transplantability.Tissue Antigens. 1971; 1: 153
- Immunotherapy of cancer: Immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.Science. 1971; 174: 591
- Immunospecific regression of methylcholanthrene fibrosarcomas with the use of neuraminidase. V. Quantitative aspects of the experimental immunotherapeutic model.Israel J. Med. Sci. 1974; 13: 71
- Regression of spontaneous mammary carcinomas using direct injections of neuraminidase and BCG.J. Surg. Res. 1972; 12: 57
- Immunotherapy of methylcholanthrene fibrosarcoma using neuraminidase.in: Fed. Proc. 30. 1971: 246
- Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase.Surgery. 1971; 70: 38
- Acceptance of phenotypically differing cultured skin in man and mice.Transplant. Proc. 1973; V: 707
- The effect of neuraminidase on the fate of transfused lymphocytes.J. Exp. Med. 1969; 129: 551
Accepted: January 29, 1974
☆Supported by Grant No. CA 11605 from the United States Public Health Service and Grant No. IM-20A from the American Cancer Society.
© 1974 Published by Elsevier Inc.